Trial intelligence / Profile preview

Desvenlafaxine for Pain in Herpes Zoster

NCT07361809Recruiting

Sponsor
Beijing Tiantan Hospital
Start
Dec 2025
Primary completion
Sep 2027
Modality
Small Molecules
Countries
1
01

Overview

Trial of desvenlafaxine in herpes zoster (HZ) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Average Numeric Rating Scale at 4 weeks. Started Dec 2025; status: recruiting.

02

Drugs

desvenlafaxine
03

Conditions

herpes zoster (HZ)

Beyond the preview

Go deeper on NCT07361809.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07361809.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call